A study of analytical biochemistry variations between COVID-19 patients with mild symptom and fatal patients in Inburi Hospital

Abstract

A study of analytical biochemistry variations between COVID-19 patients with mild symptom and fatal patients in Inburi Hospital.
Objective: To compare analytical biochemical value in COVID-19 patients between mild symptom and fatal patients.
Methods: The World Health Organization (WHO) on January 30, 2020, has declared the novel coronavirus (COVID-19) as an international public health emergency and announced this outbreak as a global pandemic on March 11, 2020. They strongly advised all countries to surveillance, prevention and control of the outbreak in order to handle the rapid increasing of COVID-19 infection rate. The COVID-19 patients have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. The laboratory performance is currently used for diagnosis, treatment monitoring and management. Designs and methods of this study used medical statistics data consists of general information and analytical blood sample results in clinical chemistry laboratory; BUN, Creatinine, Electrolyte, SGOT, SGPT and CRP. The collected data approach to gather during October, 2021 to March, 2022 among 2 groups of COVID-19 patients; mild symptom and fatal patients. Both of data sets were compared by using analytical statistics namely Cochran test and Fisher’s Exact.
Result: The result of this study found that 322 of patients with mild symptom had statistically significant difference in abnormal BUN, Creatinine, CRP and CO2. While, 27 of fatal patients performed statistically significant difference in abnormal BUN, Creatinine, SGOT, CPR, Na, K, Cl and CO2. Both of analytical data sets were evaluated and compared, the result indicated the abnormal Creatinine and CRP were major risk factors that had statistically significant difference in patients motality.
Conclusion: Based on this study, the abnormal Creatinine and CRP were major risk factors affecting the mortality of patients infected with COVID-19. Therefore, both of biochemical substances were suitable for monitoring hospitalized patients with severe disease progression probability.